Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Cash from Operations (2016 - 2025)

Myriad Genetics (MYGN) has disclosed Cash from Operations for 17 consecutive years, with 10600000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations rose 60.61% to 10600000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 1800000.0 through Dec 2025, up 120.69% year-over-year, with the annual reading at 1800000.0 for FY2025, 120.69% up from the prior year.
  • Cash from Operations for Q4 2025 was 10600000.0 at Myriad Genetics, down from 21100000.0 in the prior quarter.
  • The five-year high for Cash from Operations was 71800000.0 in Q1 2021, with the low at 54700000.0 in Q4 2023.
  • Average Cash from Operations over 5 years is 10275000.0, with a median of 8400000.0 recorded in 2021.
  • The sharpest move saw Cash from Operations crashed 1029.55% in 2022, then soared 2914.29% in 2025.
  • Over 5 years, Cash from Operations stood at 9500000.0 in 2021, then grew by 23.16% to 7300000.0 in 2022, then crashed by 649.32% to 54700000.0 in 2023, then skyrocketed by 112.07% to 6600000.0 in 2024, then surged by 60.61% to 10600000.0 in 2025.
  • According to Business Quant data, Cash from Operations over the past three periods came in at 10600000.0, 21100000.0, and 13600000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.